Cargando…

P1448: LONG-TERM SURVIVORS AFTER FAILURE OF CAR-T CELL THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL): A GLA/DRST STUDY

Detalles Bibliográficos
Autores principales:	Derigs, P., Bethge, W., Holtick, U., von Tresckow, B., Ayuk, F., Penack, O., Vucinic, V., von Bonin, M., Baldus, C., Mougiakakos, D., Wulf, G., Schnetzke, U., Stelljes, M., Thomas, S., Schroers, R., Kroeger, N., Dreger, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429516/ http://dx.doi.org/10.1097/01.HS9.0000848648.00591.47

Ejemplares similares

Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience
por: Dreger, Peter, et al.
Publicado: (2022)

Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study
por: Ayuk, Francis, et al.
Publicado: (2023)

Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study
por: Schubert, Maria-Luisa, et al.
Publicado: (2023)

Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study
por: Gagelmann, Nico, et al.
Publicado: (2022)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-DIRECTED CAR T-CELL THERAPY FOR R/R LBCL
por: Rejeski, K., et al.
Publicado: (2022)

A gating model for wildtype and R1448H Nav1.4 channels in paramyotonia
por: HOLZHERR, BORIS, et al.
Publicado: (2014)

Characterization of pyoverdine and achromobactin in Pseudomonas syringae pv. phaseolicola 1448a
por: Owen, Jeremy G, et al.
Publicado: (2011)

1448. Impact of Mental Illness on Outcomes of Outpatients with Community-Acquired Pneumonia
por: Mergenhagen, Kari, et al.
Publicado: (2018)

ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV
por: Strati, Paolo, et al.
Publicado: (2023)

1448. Characterizing Monkeypox in a Secondary Hospital in Madrid. Is HIV Playing a Role?
por: Alonso, Samuel Estévez, et al.
Publicado: (2023)

P1197: AXICABTAGENE CILOLEUCEL (AXI-CEL) IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): OUTCOMES OF THE PHASE 2 ZUMA-14 STUDY
por: Strati, P., et al.
Publicado: (2022)

P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY
por: Hutchings, Martin, et al.
Publicado: (2023)

Phylogenetic Analysis and Molecular Evolution Patterns in the MIR482-MIR1448 Polycistron of Populus L
por: Zhao, Jia-Ping, et al.
Publicado: (2012)

Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL
por: Abramson, Jeremy S., et al.
Publicado: (2022)

Complete Genome Sequence for the Fusarium Head Blight Antagonist Bacillus amyloliquefaciens Strain TrigoCor 1448
por: Nelson, Beth A., et al.
Publicado: (2014)

1448. Prostate Abscess: Clinical Features, Management, and Outcomes of a “Stealth” Infection: A Case Series
por: Wooster, Margaux E, et al.
Publicado: (2019)

Evolution of Matrix Gla and Bone Gla Protein Genes in Jawed Vertebrates
por: Leurs, Nicolas, et al.
Publicado: (2021)

P1398: AXICABTAGENE CILOLEUCEL VERSUS TISAGENLECLEUCEL CAR-T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Gagelmann, Nico, et al.
Publicado: (2023)

P1710: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TREATMENT FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PATIENT-REPORTED OUTCOMES (PRO) FROM THE PHASE 2 PILOT STUDY
por: Gordon, L. I., et al.
Publicado: (2022)

P1125: DURABLES RESPONSES ACHIEVED WITH ANTI-CD19 ALLOGENEIC CAR T ALLO-501/501A IN PHASE 1 TRIALS OF AUTOLOGOUS CAR T-NAÏVE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)
por: Munoz, Javier, et al.
Publicado: (2023)

Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL
por: Perez, Ariel, et al.
Publicado: (2022)

p.R220L Is a Likely Pathogenic Novel GLA Gene Mutation Responsible for Fabry Disease
por: Ali Barman, Hasan, et al.
Publicado: (2022)

GlaR (YugA)—a novel RpiR‐family transcription activator of the Leloir pathway of galactose utilization in Lactococcus lactis IL1403
por: Aleksandrzak‐Piekarczyk, Tamara, et al.
Publicado: (2018)

Matrix Gla Protein drives stemness and tumor initiation in ovarian cancer
por: Nieddu, V., et al.
Publicado: (2023)

Matrix Gla protein in tumoral pathology
por: GHEORGHE, SIMONA ROXANA, et al.
Publicado: (2016)

Polymorphisms in the glucocerebrosidase gene and pseudogene urge caution in clinical analysis of Gaucher disease allele c.1448T>C (L444P)
por: Brown, Justin T, et al.
Publicado: (2006)

Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution Experience
por: Trando, Aaron, et al.
Publicado: (2023)

Thymic hyperplasia after mRNA based Covid-19 vaccination
por: von Tresckow, Julia, et al.
Publicado: (2021)

1448. Forgiveness of BIC/FTC/TAF: In Vitro Simulations of Intermittent Poor Adherence Find Limited HIV-1 Breakthrough and High Barrier to Resistance
por: Mulato, Andrew, et al.
Publicado: (2020)

P1744: ACCURACY OF PREDICTING LONG-TERM SURVIVAL OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPIES IN LARGE B-CELL LYMPHOMA (LBCL)
por: Verburg-Baltussen, E. J., et al.
Publicado: (2022)

A novel double GLA gene mutation of W24R and N419D in a patient with cardiac Fabry disease
por: Hirose, Masanori, et al.
Publicado: (2023)

A Korean family with Arg1448Cys mutation of SCN4A channel causing paramyotonia congenita: electrophysiologic, histopathologic, and molecular genetic studies.
por: Kim, Dae-Seong, et al.
Publicado: (2002)

Two Homologues of the Global Regulator Csr/Rsm Redundantly Control Phaseolotoxin Biosynthesis and Virulence in the Plant Pathogen Pseudomonas amygdali pv. phaseolicola 1448A
por: Ramírez-Zapata, Diana, et al.
Publicado: (2020)

P1448: CHARACTERISATION OF QUALITY OF LIFE-LINKED PATIENT-REPORTED OUTCOMES THROUGH A DIGITAL AND CONTINUOUS REMOTE MONITORING ECOSYSTEM IN SICKLE CELL DISEASE.
por: Summers, Kim, et al.
Publicado: (2023)

P1381: EARLY FULL DONOR CHIMERISM AFTER FLAMSA RIC BASED ALLOGENEIC HSCT BUT NOT PRESENCE OF MORPHOLOGICAL REMISSION ASSOCIATES WITH OUTCOMES IN R/R AML PATIENTS
por: Ussmann, J., et al.
Publicado: (2022)

Enantioselective sulfoxidation using Streptomyces glaucescens GLA.0
por: Salama, Sara, et al.
Publicado: (2020)

Phenotypes of undiagnosed adults with actionable OTC and GLA variants
por: Gold, Jessica I., et al.
Publicado: (2023)

Assessment of Peripheral Nervous System Alterations in Patients with the Fabry Related GLA-Variant p.A143T
por: Godel, Tim, et al.
Publicado: (2020)

CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany
por: Bader, Peter, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4i5jt8jmmt1ftt6beaq77vdn25